LuceBridge ELISA   For Lucentis Biosimilar Comparision 

Complete kit for the systematic 3-D conformational comparability analysis of 

Lucentis biosimilar molecule to Ranibizumab (Lucentis trade name)

Ranibizumab is a humanized IgG1 monoclonal antibody fragment (Fab) created from the same parent antibody as Bevacizumab (Avastin). It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. 

This kit will allow for conformational comparison between Lucentis Biosimilars and authentic Ranibizumab.  

AB000214     LuceBridge ELISA (for Lucentis Biosimilar Comparision)     1 Kit

☞   Click here for the detailed product instruction

☞   Click here for LuceBridge MSDS